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The Binding Site of NK Receptors
on HLA-C Molecules
Ofer Mandelboim,* Hugh T. Reyburn,* Eric G. Sheu, 1995; Biassoni et al., 1996). NK cell inhibitory receptors
(NKIR, p58 or p70 molecules) have an uncharged trans-Mar ValeÂ s-GoÂ mez, Daniel M. Davis, Laszlo Pazmany,
and Jack L. Strominger membrane anchor and a long cytoplasmic tail containing
two ITIM motifs. Binding of the NKIR to class I MHCDepartment of Molecular and Cellular Biology
Harvard University proteins leads to the recruitment of protein tyrosine
phosphatases such as PTP1C and PTP1D and the gen-Cambridge, Massachusetts 01238
eration of a negative signal, which blocks NK cell killing
(Burshtyn et al., 1996; Campbell et al., 1996; Fry et al.,
1996; Olcese et al., 1996). NK cell-activating receptorsSummary
(NKAR, p50 molecules) have a transmembrane domain
containing a lysine residue and a truncated cytoplasmicThe protection of cells expressing class I HLA mole-
domain lacking the two ITIM motifs (Wagtmann et al.,cules from NK lysis is mediated by natural killer cell
1995; Biassoni et al., 1996). Engagement of NKAR byinhibitory receptors (NKIR). Using site-directed muta-
class I MHC protein results in activation of the cell bygenesis, residues on HLA-C that determine the locus
an as yet uncharacterized signaling pathway. Moreover,specificity (aVal-76), allotype group specificity (a di-
the distribution of these molecules is not limited to NKmorphism aAsn-80/Lys-80), and affinity of NKIR bind-
cells; their representation on subsets of T cells resultsing (a second pair of dimorphisms, aAla-73, Asp-90 or
in novel inhibitory or activating functions (Phillips et al.,aThr-73, Ala-90) have been identified. Thus the ªfoot-
1995; Mandelboim et al., 1996a).printº of the NKIR on the a1 helix of the class I MHC
A binding site of the NK receptor molecules on HLAmolecule HLA-C and its associated b strands are simi-
was first located by experiments that revealed that thelar in position to the site occupied by superantigens
patterns of class I HLA-mediated inhibition of NK cellson and behind the a1helix of the class II MHC molecule
could be correlated with a dimorphism of amino acidHLA-DR1, but further toward its C-terminus. The inter-
residues 77 and 80 of the a1 helix of HLA-C moleculesmediate affinity binding of NKIR to HLA-C, determined
(Colonna et al., 1993a, 1993b). More specifically, theby a73 and a90, has an essential role in preventing
residue at a80 divides HLA-C alleles into two groupscross-reactivity and ensuring the availability of NK
encoding either aAsn-80 or aLys-80, which are able tocells for immunosurveillance; low affinity and high af-
inhibit separate subsets of NK cell clones, NK1- andfinity mutants are both physiologically impaired.
NK2-specific cells that express p58 molecules NKIR1
and NKIR2 (Mandelboim et al., 1996b). The pattern ofIntroduction
residues in a similar region of HLA-B molecules (a77±83)
controls the interaction of these HLA-B proteins with theNatural killer (NK) cells, as well as cytotoxic T cells,
p70 molecule, NKIR3. NK3-specific cells are inhibited byare major components of the mechanism by which an
HLA-B allotypes containing aIle-80 (that express theimmune response leads to the destruction of foreign or
serologically defined Bw4 determinant) (Cella et al.,infected tissue (Trinchieri, 1989). NK cells and T cells
1994; Gumperz et al., 1995). NK4-specific cells alsoarise from a common progenitor and express several
recognize Bw4-expressing cells, but require aThr-80cell surface molecules in common (Sanchez et al., 1994;
(Luque et al., 1996). NK cells in the NK5 group recognizeSpits et al., 1995). Moreover, the effector functions of
HLA-A3 (Dohring et al., 1996; Pende et al., 1996).cytotoxic T cells (CTL) and NK cells are controlled by a
To identify the precise structural characteristics re-common ligand, class I major histocompatibility com-
quired for inhibition of specific NK cells by HLA-C, weplex (MHC) glycoproteins (Ljunggren and Karre, 1990;
have performed an extensive mutagenesis analysis ofTownsend and Bodmer, 1989). CTL become activated
the C-terminal portion of the a1 helix of HLA-Cw6for lysis after recognition of novel peptide fragments
(aLys-80, NK1 protection) and HLA-Cw7 (aAsn-80, NK2bound to class I MHC molecules (Townsend and
protection). The ability of these mutants to inhibit lysisBodmer, 1989). NK cells are active in the absence of
by NK1- and NK2-specific NK lines and clones was thenclass I MHC proteins on target cells (Ljunggren and
tested in killing assays. In the present experiments, keyKarre, 1990), i.e., in contrast with CTL, they are inhibited
residues for control of recognition by both NK1 and NK2by recognition of class I MHC molecules.
effector cells at positions a73, a76, and a90, in additionRecognition of polymorphic determinants on HLA
to the allotype group±specific residue a80, were definedmolecules by human NK cells is mediated by a novel
and their normal physiological function was described.family of class I MHC±binding receptors that share a
high degree of homology and are members of the immu-
noglobulin superfamily (Colonna and Samaridis, 1995; Results
D'Andrea et al., 1995; Wagtmann et al., 1995). Two dis-
crete isoforms of NK receptors exist in which similar The Amino Acid Residue at a76 of HLA-C
extracellular portions are attached to different trans- Alleles Controls the Locus Specificity
membrane and cytoplasmic regions (Moretta et al., of the NKIR±HLA-C Interaction
The water-accessible amino acid found on the a1 helix
at a80 of HLA-C alleles has previously been shown to*These authors contributed equally to this work.
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Table 1. Residues between a73 and a90 in HLA Alleles Controlling NK Cell Recognition
73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
Cw NK1 Inhibitors
2 T D R V N L R K L R G Y Y N Q S E A
4 A D R V N L R K L R G Y Y N Q S E D
5 T D R V N L R K L R G Y Y N Q S E A
6 A D R V N L R K L R G Y Y N Q S E D
NK2 Inhibitors
1 T D R V S L R N L R G Y Y N Q S E A
3 T D R V S L R N L R G Y Y N Q S E A
7 A D R V S L R N L R G Y Y N Q S E D
8 T D R V S L R N L R G Y Y N Q S E A
NK3 Inhibitors (Bw4)
B58 T D R E N L R I A L R Y Y N Q S E A
NK? (Bw6)
B07 T D R E S L R N L R G Y Y N Q S E A
Cells expressing HLA-Cw2, 4, 5, and 6 are protected from lysis by NK1 clones, while those expressing HLA-Cw1, 3, 7, and 8 are protected
from lysis by NK2 clones. HLA-B allotypes sharing the Bw4 epitope protect from lysis by NK3 clones. No NK specificity for HLA alleles carrying
the Bw6 epitope is presently defined. Polymorphic amino acids in the various HLA molecules are shown in bold.
be a key residue controlling recognition by both NK1- extent. Further, the various NK lines and clones behaved
in the killing assay exactly as predicted from their NKIRand NK2-specific NK cells (Mandelboim et al., 1996b).
However, the actual footprint of the NK receptor on phenotype, i.e., NK1 cells were inhibited by the expres-
sion of HLA-Cw6 and NK2 cells by the expression ofHLA-C is likely to be larger than a single amino acid.
Inspection of HLA-C sequences (Table 1) suggested that HLA-Cw7. The inhibition by Cw6 was reversed by the
NKIR1 MAb EB6, but not by GL183, and that by Cw7aVal-76, found in all HLA-C alleles and also located at
the top of the a1 helix, may be important in the NKIR- was reversed by the NKIR2 MAb GL183, but not by EB6.
Importantly, mutants of Cw6 or Cw7 expressing eitherHLA interaction. aGlu-76 is found in virtually all HLA-B
alleles (see Discussion). HLA-C molecules, which have aGlu-76 or aGly-76 (Cw6/V76E, Cw6/V76G, Cw7/V76E,
and Cw7/V76G) were unable to inhibit lysis by any ofaVal-76 such as HLA-Cw1, 3, 7, and 8, are protected
from lysis by NK2 cells, whereas HLA-B alleles such as the NK lines and clones tested (NK1 and NK2 cells).
Thus, a76 was shown to be an important residue influ-HLA-B7 or HLA-B8 (which encode the Bw6 epitope and
are identical to HLA-C [NK2] molecules through a77±89, encing recognition of HLA-C by both NK1 and NK2 cells.
but have aGlu-76) do not protect from lysis by NK2 cells
(Colonna et al., 1993a).
To assess the role of a76 in the NKIR±HLA-C interac- A Second Dimorphism of Amino Acids
at a73 and a90 Influences the Affinitytion, aVal-76 in the NK1- and NK2-protecting alleles
(HLA-Cw6 and HLA-Cw7, respectively) was replaced of the NKIR±MHC Interaction
The recognition site of the NKIR on HLA-C might bewith glutamic acid, the residue found in HLA-B alleles,
or glycine. Mutants Cw6/V76E and Cw6/V76G have the similar in position to the sites occupied by staphylococ-
cal enterotoxin B (Jardetzky et al., 1994) and toxic shockCw6 backbone, but express glutamic acid or glycine at
a76, respectively, whereasmutants Cw7/V76E and Cw7/ syndrome toxin-1 (Kim et al., 1994) on top of and behind
the a1 helix of class II MHC molecules, but closer to theV76G have the Cw7 backbone. These mutant constructs
were transfected into class I-negative 721.221 cells, and C-terminus of the helix (Mandelboim et al., 1996b). aVal-
65 in HLA-DR, with which TSST-1 interacts, is equivalentthe level of HLA-C expression of the various transfec-
tants was monitored by staining using the monoclonal in position to aThr-73/Ala-73 in HLA-Cw3/7. Further-
more, the pairof residues found at a73 and a90 of HLA-Cantibody (MAb) W6/32 (Figure 1A). 721.221 cells, as well
as cells transfected with the empty pCDNA3 vector, did molecules comprise a seconddimorphism in HLA-C (Ta-
ble 1). All HLA-C molecules contain either aAla-73 cose-not express detectable levels of class I MHC molecules.
To test the role of a76 in NK recognition of HLA-C, gregating with aAsp-90 or aThr-73 cosegregating with
aAla-90, i.e., aAla-73, Asp-90, or aThr-73,Ala-90.NK lines and clones were generated from donors MV
and OM. The NKIR phenotypes of the NK clones used To examine the role of these paired dimorphisms in
NKIR±HLA-C interactions, we carried out site-directedin this work were assessed by staining with the MAb
EB6 (NK1 specific) and GL183 (NK2 specific) (Figure 2). mutagenesis to change aAla-73 to aThr-73 in both Cw6
and Cw7 (Cw6/A73T, Cw7/A73T) and aAsp-90 to aAla-90All NK lines and clones were 100% CD3 negative and
CD56/CD16 positive. Figure 3 shows a representative in both alleles (Cw6/D90A, Cw7/D90A). Double mutants
were also constructed, i.e., Cw6/A73T,D90A and Cw7/killing assay performed in the presence and absence of
either NKIR1 MAb EB6 or NKIR2 MAb GL183. 721.221 A73T,D90A. These mutant constructs were also trans-
fected into 721.221 cells (Figure 1B).cells, a standard target for NK lysis, were killed by all
lines and clones, with or without antibodies, to the same The behavior of the a73, 90 dimorphism mutants in
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Figure 1. HLA-C Expression on the Various Transfectants
721.221 cells were transfected with wild-type HLA-Cw6 or HLA-Cw7
and with various HLA-Cw6 or HLA-Cw7 mutants at a76 (A), a73,
and/or a90 (B). Transfections were performedas described in Exper-
imental Procedures. Recipient cells (721.221) and the various
transfectants were stained with W6/32 antibody, followed by fluo-
rescein isothiocyanate (FITC)-labeled sheep anti±mouse immuno-
globulin G (IgG) antibody (bold lines). Controls were the same cells
stained with FITC anti±mouse IgG alone (light lines).
killing assays was then examined (Figure 4). Cells ex- alleles is not absolute. Both p58 molecules (NKIR1 and
pressing single mutants at a90 (aA73, D90A) in both NKIR2) could recognize HLA-C alleles with either aLys-
Cw6 and Cw7 alleles were lysed by all NK lines and 80 or aAsn-80 when the additional mutation at a73 was
clones tested; they could not inhibit, suggesting that this introduced.
residue is a contact residue in theNKIR±MHC interaction To confirm these data, the same mutants were tested
(Figures 4A±4E). In contrast, a73 mutants behaved as with the OM9 clone, which expresses both NKIR1 and
ªsuper-inhibitors.º Cw6/A73T and Cw7/A73T transfec- NKIR2 proteins (Figure 2). As expected, this clone was
tants (i.e., expressing aA73T, D90 proteins) were pro- inhibited by both Cw6 and Cw7 and by both Cw6/A73T
tected from lysis by both NK1- and NK2-specific effector and Cw7/A73T. The inhibition achieved by Cw6/A73T
cells (Figure 4). In both cases, however, inhibition of the or Cw7/A73T could not be reversed with saturating
homologous NK-specific cell was more profound than amounts of either NKIR1 or NKIR2 MAb, indicating that
the cross-reactive NK cell. Moreover, lysis of Cw6/A73T each of these mutants bound to both NKIR and, more-
by NK1-specific effectors was only partially restored in over, that inhibitory signals resulted from binding toeach
the presence of saturating amounts of the NKIR1 MAb (Figure 4E).
EB6, suggesting an increase in affinity (Figures 4A and
That treatment with NKIR-specific MAb could com-
4B), and not at all by GL183. Conversely, lysis of the
pletely block cross-reactive binding of Cw6/A73T andsame Cw6/A73T transfectant mediated by NK2-specific
Cw7/A73T, but only partially reverse the specific NKIReffector cells was inhibited and completely restored by
interaction with the Cw6 and Cw7 mutants, stronglyNKIR2 MAb GL183 (Figures 4C and 4D). Reciprocally,
suggested that the sequences in the a73 mutant con-saturating amounts of the NKIR2 MAb GL183 failed to
structs resulted in high affinity interactions betweencompletely restore lysis of Cw7/A73T by NK2 cells (Fig-
HLA-C and NKIR. To test this hypothesis, we carriedures 4C and 4D), but MAb EB6 completely abrogated
out experiments to assess MAb-mediated reversal ofthe ability of Cw7/A73T transfectant to inhibit killing by
inhibition over a range of MAb concentrations (FiguresNK1 lines and clones (Figures 4A and 4B). These experi-
5A and 5B). In each case, about ten times as muchments provide direct evidence that allotypegroup speci-
ficity defined by the amino acid found at a80 of HLA-C MAb was required to reverse the class I MHC±mediated
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Table 2. Key Residues in HLA-C Alleles Controlling NK
Specificity
Lysis by
clones
73 76 80 90 NK1 NK2
Cw6 A V K D 2 1
3/4 2/4
Cw6/A73T T V K D 2 2
4/4 3/4
Cw6/V76E A E K D 1 1
2/4 1/4
Cw6/K80N A V N D 1 2
2/4 3/4
Cw6/D90A A V K A 1 1
2/4 1/4
Cw6/A73T,D90A T V K A 2 1
3/4 2/4
Cw7 A V N D 1 2
2/4 3/4
Cw7/A73T T V N D 2 2
3/4 4/4
Cw7/V76E A E N D 1 1
1/4 2/4
Cw7/N80K A V K D 2 1
3/4 2/4
Cw7/D90A A V N A 1 1
1/4 2/4
Cw7/A73T,D90A T V N A 1 2
2/4 3/4
Mutant HLA-C molecules and various transfectants of 721.221 cells
were generated as described, and lysis by NK1 and NK2 clones
was examined. Plus, lysis; minus, no lysis (inhibition). The fraction
of residues that conform to the highest affinity ligands, TVKD or
TVND, are shown.
Figure 2. NKIR Expression on NK Clones
NK clones OM9, OM32, and OM49 were stained with the p58-spe- NKIR2 was inhibited by both double mutants Cw6/
cific MAbs EB6 (NKIR1, bold lines) and GL183 (NKIR2, dotted lines), A73T,D90A and Cw7/A73T,D90A. With this latter clone,
followed by FITC anti±mouse IgG antibody (bold lines). Controls
lysis of Cw6/A73T,D90A transfectants was restored bywere the same cells stained with FITC anti±mouse IgG alone (light
MAb EB6 but not MAb GL183; conversely, lysis of Cw7/lines).
A73T,D90A transfectants was restored by GL183 but
not by EB6 (Figure 4E). Thus, the loss of the putative
hydrogen bond by the aD90A mutation was compen-
sated in the double mutants by the aA73T mutations,inhibition by 50%, i.e., an apparent increase in affinity
adding a salt bridge or a hydrogen bond, i.e., secondof around 10-fold was observed.
site reversion.
Second Site Reversion Residues Surrounding a80 Do Not Interact
Thus, a73 and a90 both modulate the affinity of the with NKIR Molecules
NKIR±MHC interactions. One plausible hypothesis is NK3-specific NK cells interact with the Bw4 motif found
that the NK receptor has to form hydrogen bonds with on some HLA-B alleles. The Bw4 epitope is character-
a80 and either a73 or a90; the absence of either one ized at a78±83 by amino acids LRIXLR or LRTXLR. In
of these two contacts will lead to loss of interaction, contrast, HLA-C alleles (and HLA-B alleles encoding the
whereas binding to both residues a73 and a90 (three Bw6 epitope) express a characteristic motif surrounding
contacts) will result in too strong an interaction, with a80 at a78±82, LRXLR. To test the role of the LRXLR
consequent loss of specificity. Testing of the double motif in NKIR±MHC recognition, each of the amino acids
mutants aA73T, D90A in killing assays confirmed this at positions a78, a79, a81, and a82 was mutated to
line of reasoning. Cw6/A73T,D90A specifically inhibited alanine in both Cw6 and Cw7 alleles, generating the
lysis by NK1 cells, but not NK2 effectors, and this protec- mutants Cw6/L78A, Cw6/R79A, Cw6/L81A, Cw6/R82A,
tive effect was lost upon addition of NKIR1 MAb EB6. Cw7/L78A, Cw7/R79A, Cw7/L81A, and Cw7/R82A. All
Conversely, Cw7/A73T,D90A-expressing cellswere pro- mutants were transfected into 721.221 cells (Figure 6)
tected from lysis by NK2 cells, but not NK1-specific and then assayed against a panel of NK lines and clones.
killers, and lysis was restored by NKIR2 MAb GL183 All mutants behaved like the wild-type Cw6 and Cw7
transfectants (Figure 7), indicating no specific role for(Figures 4A±4D). OM9 that expresses both NKIR1 and
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Figure 3. aVal-76, the Locus-Specific Resi-
due, of HLA-C Allotypes Is Essential for Inhi-
bition of NK1- and NK2-Specific NK Cells
(A) MV NK line (group 1 specificity); (B) OM32
clone (group 1 specificity); (C) OM NK line
(group 2 specificity); (D) OM49 NK clone
(group 2 specificity); (E) OM9 clone (group 1
and 2 specificity). NK lines and clones pre-
pared from donor MV (A) or from donor OM
(B±E) were incubated with various [35S]methi-
onine-labeled target cells for 5 hr at various
E:T ratios, with or without antibodies (GL183
or EB6 at 5 mg/ml). The targets are un-
transfected 721.221 cells or 721.221 cells
transfected with the cDNAs shown. Only the
data obtained at an E:T ratio of 10:1 (for the
lines) and 5:1 (for the clones) are shown. One
out of three representative experiments is
shown.
the LRXLR motif in the recognition of HLA-C by p58 Thus, the combination of aVal-76 and aAsn-80/Lys-80
is HLA-C specific (with two exceptions, the interlocusNKIR1 or NKIR2.
recombinant HLA-B*4601 [Barber et al., 1996] and the
unusual HLA-B allele HLA-B*7301 [Parham et al., 1994;Discussion
Vilches et al., 1994]).
The nature of the amino acid residues found at a73Four key residues, a73, a76, and a90, in addition to the
dimorphic a80 that determines allotypegroup specificity and a90 represents a second paired dimorphism in
HLA-C alleles that was not obviously associated with(Mandelboim et al., 1996b), define the NKIR interaction
site on HLA-C (Figure 8). These are water-accessible NK cell recognition, i.e., HLA-C alleles have either aThr-
73, Ala-90 or aAla-73, Asp-90, as found in both Cw6residues found either on the top of the a1 helix (a73, a76,
and a80) or at the end of the loop (a90) that connects the and Cw7 (Table 1). Replacement of aAsp-90 by alanine
in Cw6 and Cw7 resulted in loss of inhibition for bothC-terminus of the a1 helix to the first strand of the b
sheet of the a2 domain. a76 is a locus-specific residue, alleles, i.e., inability to interact with NKIR. Strikingly, this
loss of function mutation (aD90A) could be compen-valine in HLA-C alleles and glutamic acid in most HLA-B
alleles. Mutation of this residue from valine to either sated by a mutation at a distant site, aA73T. Lysis of
NK1 and NK2 clones was inhibited by Cw6/A73T,D90Aglutamic acid or glycine in both Cw6 and Cw7 resulted
in loss of inhibition and lysis by both NK1 and NK2 and Cw7/A73T,D90A, respectively. A single hydrogen
bond or a salt bridge at either one of these sites isclones. That neither glutamic acid (as found in most
HLA-B alleles) nor glycine is tolerated at this position therefore essential for the NKIR-HLA-C interaction.
Both Cw6 and Cw7 bearing both hydrogen bond do-suggests that hydrophobic interactions are involved in
the NKIR-HLA-C interaction at this site. HLA-A alleles nors as a result of single A73T mutations were able to
inhibit both NK1 and NK2 clones. This cross-reactiveencode valine at a76, as well as alanine or threonine,
and a few HLA-B alleles also encode aVal-76. However, inhibition was the result of interaction with NKIR, since
it could be reversed by treatment of the NK clone withaAsn-80 or Lys-80 never occurs in these sequences.
Immunity
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Figure 4. The Amino Acids at a73 and a90
Are Critical Components of the Interaction of
HLA-C Allotypes with NK1- and NK2-Specific
NK Cells
(A) MV NK line (group 1 specificity); (B) OM32
clone (group 1 specificity); (C) OM NK line
(group 2 specificity); (D) OM49 NK clone
(group 2 specificity); (E) OM9 clone (group 1
and 2 specificity). For experimental details
see the legend to Figure 3.
MAb specific for the NKIR expressed by that clone. That inhibitory ligand must be rapid and, second, that the
inhibitory signals are short-lived. Similarly, alteration inan interaction between NKIR and the ªsuper-inhibitorº
mutant HLA-C molecules can be detected may not be the adhesive properties of NK cells mediated by other
molecules may have drastic effects on their functionsurprising given the high degree of homology among
NKIR molecules, even those with apparently distinct (Chambers et al., 1996).
If three of the four key residues at a73, a76, a80, andbinding specificities. That HLA-C molecules expressing
the super-inhibitor motif do not occur in human popula- a90 are present in an HLA-C molecule, then NK receptor
binding will occur and killing by the clone expressingtions may be because the intermediate affinity of the
naturally occurring receptors is optimal to avoid cross- that receptor will be inhibited. Forexample, in the interlo-
cus recombinant HLA-B*4601, HLA-B-specific and HLA-reactivity between allotype groups. The intermediate af-
finity may also serve to facilitate recirculation of NK cells. C-specific sequences have been recombined so that
residues 66±76 of the a1 helix of HLA-Cw*0102 (NK2Physiologically, NK cells must attach to their target, be
inhibited when the NKIR is liganded by an appropriate specificity) were inserted into the HLA-B*1501 se-
quence. As a result, the HLA-C locus-specific residueclass I MHC protein, and then detach to continue their
immunosurveillance function. If the ligand-receptor in- aVal-76 is present instead of the B locus-specific resi-
due aGlu-76. This recombinant molecule also encodesteraction had too high an affinity, then this essential
physiological role might be compromised. The addition the affinity residues aThr-73,Ala-90 and the HLA-C allo-
type group±specific residue aAsn-80. Accordingly, lysisof even very large numbers of bystander cells express-
ing inhibitory HLA-C ligands to a system in which lysis by NK2 clones of 721.221 cells transfected with the HLA-
B*4601 allele was inhibited (Biassoni et al., 1995; Barberof HLA-C-deficient targets is taking place does not in-
hibit the lysis of the labeled targets at all (Colonna et et al., 1996). Genetic manipulation of a xenograft to
cause expression of the high affinity ªcross-protectiveºal., 1993a), indicating, first, that the dissociation of the
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HLA-C molecule encoding aThr-73,Asp-90 might be
useful in protecting that graft from NK cell attack.
These residues localize the binding site of NK recep-
tors on the MHC protein on and behind the a1 helix in
a very similar position to that of the binding site for the
staphylococcal superantigen TSST-1 on class II MHC
proteins (Kim et al., 1994), C-terminal to the binding site
of staphylococcal enterotoxin B (Jardetzky et al., 1994).
Peptide seems to have no positive role in binding, since
cell surface expression of human class I MHC molecules
in the absence of peptide is sufficient to inhibit NK cell
killing (Mandelboim et al., 1996b). Peptides might, how-
ever, have an effect on target cell lysis (Peruzzi et al.,
1996) if they are able to interfere with binding of the
NKIR at one of the key contact residues and, notably,
TSST-1 does interact with the C-terminus of the bound
peptide. Indeed, using TAP-deficient RMA-S cells trans-
fected with HLA-Cw7, the presence of a lysine residue
at P8 of several viral and self-peptides abolished recog-
nition by NK2 cells (Mandelboim et al., submitted). P8
points upward and is immediately adjacent to the impor-
tant NKIR contact residue a80, while P9 points down-
ward and is buried in a pocket.
Finally, these data emphasize yet again the special
ability of molecules containing the MHC fold to bind to
other proteins. b2-microglobulin binds under the a1 and
a2 domains of class I MHC proteins, where it interacts
with the a3 domain, peptides bind in the groove, CD8
(or CD4) binds to the a3 domain (Salter et al., 1990) (or
the b2 domain of class II MHC proteins; Cammarota et
al., 1992; Konig et al., 1992), and TCR binds on the top
of the a1 and a2 domains (or a1 and b1 domains of
class II MHC proteins) (Garboczi et al., 1996; Garcia etFigure 5. Reversal of Inhibition
al., 1996). The MHC-related neonatal receptor for IgG
Mutants Cw6/A73T,D90 (A) and Cw7/A73T,D90 (B) were used at
binds its ligand via the ends of the a1 and a2 domainsdifferent concentrations of the MAb EB6 and GL183. For experimen-
(Burmeister et al., 1994a, 1994b), and the present datatal details see the legend to Figure 3.
indicate that NK receptors bind to class I MHC mole-
cules on a surface similar to that to which superantigens
Figure 6. Cell Surface Expression of HLA-C
Allotypes and Mutants at a78, a79, a81,
and a82
For experimental details see the legend to
Figure 1.
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Figure 7. a78, a79, a81, and a82 of HLA-C
Allotypes Do Not Affect Recognition by NK1
and NK2 Clones
For experimental details see the legend to
Figure 3. Only an E:T ratio of 5:1 is shown.
were obtained from healthy adult donors MV (A2, A11; B18, B44;bind on class II MHC proteins. Thus, molecules express-
Cw5), NQ (A1, A29; B35, B51, Cw4), HTR (A1, A2; B7, B8; Cw7), DPing the ªMHC foldº bind specifically to many other mole-
(A1, A3, B7, B8, Cw7), AH (A1, A3, B8, B62, Cw9), and OM (A2, B44,cules, each utilizing a different aspect of its surface.
B39, Cw5, Cw7). NK lines and clones were prepared as previously
described (Mandelboim et al., 1996b).
Experimental Procedures
Cells and Antibodies Mutagenesis
cDNAs encoding HLA-Cw*0602 and HLA-Cw*0702 were generatedThe class I MHC-negative human B cell line 721.221 (Shimizu and
DeMars, 1989) was obtained from the ATCC. MAbs GL183 and EB6 via RT-PCR using RNA isolated from the B cell lines LBF (Cw6) and
JY (Cw7), cloned into M13mp18, and sequenced fully. Mutagenesis(Moretta et al., 1993) were purchased from Immunotech. NK cells
Figure 8. The Locations of the Four Key
HLA-C Residues That Affect Its Interaction
with NKIR1 and NKIR2
Residues a73, a76, a80, and a90 are high-
lighted on an a-carbon diagram of a class I
MHC molecule, viewed from the top (Bjork-
man et al., 1987).
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Table 3. Sequences of the Oligonucleotide Primers Used for the D., Conte, R., Di Donato, C., Parham, P., and Moretta, L. (1995).
Amino-acid substitutions can influence the natural killer (NK)-medi-Generation of HLA-C Mutants
ated recognition of HLA-C molecules: role of serine 77 and lysine
Mutation Primer sequence 80 in the target cells protection from lysis mediated by `group 1' or
`group 2' NK clones. J. Exp. Med. 182, 605±609.1 Cw6/A73T 59-CACTCGGTCAGTCTGTGCCTG-39
2 Cw6/V76E 59-CCGCAGGTTCTCTCGGTCAGC-39 Biassoni, R., Cantoni, C., Falco, M., Verdiani, S., Bottino, C., Vitale,
3 Cw6/V76G 59-CCGCAGGTTCCCTCGGTCAGC-39 M., Conte, R., Poggi, A., Moretta, A., and Moretta, L. (1996). The
4 Cw6/L78A 59-CAGTTTCCGCGCGTTCACCTG-39 human leukocyte antigen (HLA)-C-specific `activatory' or `inhibitory'
5 Cw6/R79A 59-GCGCAGTTTCGCCAGGTTCAC-39 natural killer cell receptors display highly homologous extracellular
6 Cw6/L81A 59-GTAGCCGCGCGCTTTCCGCAG-39 domains but differ in their transmembrane and intracytoplasmic
7 Cw6/R82A 59-CTAGTAGCCGGCCAGTTTCCG-39 portions. J. Exp. Med. 184, 645±650.
8 Cw6/D90A 59-GTGAGACCCGGCCTCGCTCTG-39 Bjorkman, P., Saper, M., Samraoui, B., Bennett, W., Strominger, J.,
and Wiley, D. (1987). Structure of the human class I histocompatibil-9 Cw7/A73T 59-CACTCGGTCAGTCTGTGCCTG-39
ity antigen, HLA-A2. Nature 329, 506±512.10 Cw7/V76E 59-CCGCAGGCTCTCTCGGTCAGC-39
11 Cw7/V76G 59-CCGCAGGCTCCCTCGGTCAGC-39 Burmeister, W.P., Gastinel, L.N., Simister, N.E., Blum, M.L., and
12 Cw7/L78A 59-CAGGTTCCGCGCGCTCACCTG-39 Bjorkman, P.J. (1994a). Crystal structure at 2.2 AÊ resolution of the
13 Cw7/R79A 59-GCGCAGGTTCGCCAGGCTCAC-39 MHC-related neonatal Fc receptor. Nature 372, 336±343.
14 Cw7/L81A 59-GTAGCCGCGCGCGTTCCGCAG-39 Burmeister, W.P., Huber, A.H., and Bjorkman, P.J. (1994b). Crystal
15 Cw7/R82A 59-GTAGTAGCCGGCCAGGTTCCG-39 structure of the complex of rat neonatal Fc receptor with Fc. Nature
16 Cw7/D90A 59-GTGAGACCCGGCCTCGCTCTG-39 372, 379±383.
The mutagenized codon is shown in bold. Burshtyn, D.N., Scharenberg, A.M., Wagtmann, N., Rajagopalan, S.,
Berrada, K., Yi, T., Kinet, J.-P., and Long, E.O. (1996). Recruitment
of tyrosine phosphatase HCP by the killer cell inhibitory receptor.
Immunity 4, 77±85.
was carried out using the Sculptor in vitro mutagenesis kit (Amer- Cammarota, G., Scheirle, A., Takacs, B., Doran, D.M., Knorr, R.,
sham) according to the instructions of the manufacturer. The se- Bannwarth, W., Guardiola, J., and Sinigaglia, F. (1992). Identification
quences of the mutagenic oligonucleotides used and the corre- of a CD4 binding site on the b2 domain of HLA-DR molecules. Nature
sponding mutants are shown in Table 3. Double mutants Cw6/ 356, 799±801.
A73T,D90A and Cw7/A73T,D90A were generated from the single
Campbell, K.S., Dessing, M., Lopez-Botet, M., Cella, M., and Co-
mutants CW6/A73T and Cw7/A73T using primers 8 and 16, respec-
lonna, M. (1996). Tyrosine phosphorylation of a human killer inhibi-
tively (Table 3). The wild-type Cw6 and Cw7 genes and all the mu-
tory receptor recruits protein tyrosine phosphatase 1C. J. Exp. Med.
tants were subcloned from M13 into pCDNA3 (Invitrogen) for trans-
184, 93±100.
fection. The sequences of all mutants were verified by sequencing
Cella, M., Longo, A., Ferrara, G.B., Strominger, J.L., and Colonna,three times: during mutagenesis in M13, after introduction into the
M. (1994). NK3-specific natural killer cells are selectively inhibitedtransfection vector, and after transfection into 721.221 cells (data
by Bw4-positive HLA alleles with isoleucine 80. J. Exp. Med. 180,not shown).
1235±1242.
Transfection Chambers, B., Salcedo, M., and Ljunggren, H.-G. (1996). Triggering
Stable 721.221 transfectants expressing wild-type or mutant HLA-C of natural killer cells by the costimulatory molecule CD80 (B7-1).
molecules were generated as previously described (Mandelboim Immunity 5, 311±317.
et al., 1996b; Pazmany et al., 1996). Surface expression of HLA-C Colonna, M., and Samaridis, J. (1995). Cloning of immunoglobulin
molecules was analyzed by flow cytometry using the pan±class I superfamily members associated with HLA-C and HLA-B recogni-
MAb W6/32. Clones exhibiting the highest levels of HLA-C expres- tion by human natural killer cells. Science 268, 405±408.
sion were used as targets in cytolytic assays.
Colonna, M., Borsellino, G., Falco, M., Ferrara,G.B., and Strominger,
J.L. (1993a). HLA-C is the inhibitory ligand that determines dominantCytolytic Assays
resistance to lysis by NK1- and NK2-specific natural killer cells.
The cytolytic activity of NK lines and clones against the various
Proc. Natl. Acad. Sci. USA 90, 12000±12004.
HLA-C transfectants and mutants was assessed in 5 hr 35S release
Colonna, M., Brooks, E.G., Falco, M., Ferrara, G.B., and Strominger,assays as previously described (Mandelboim et al., 1996b). Sponta-
J.L. (1993b). Generation of allospecific natural killer cells by stimula-neous release was less than 25% of maximal release. Each experi-
tion across a polymorphism of HLA-C. Science 260, 1121±1124.ment was repeated three to six times. Error was under 5% of the
mean of the triplicates. In experiments where NKIR-specific MAbs D'Andrea, A., Chang, C., Franz-Bacon, K., McClanaham, T., Phillips,
were used to block MHC±NKIR interaction, MAb was included in J.H., and Lanier, L.L. (1995). Molecular cloning of NKB1: a natural
the medium to a final concentration of 5 mg/ml. killer cell receptor for HLA-B allotypes. J. Immunol. 155, 2306±2313.
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